PSY7 Cost-Minimisation Analysis of Recombinant Factor VIII FC Fusion Protein Versus Emicizumab for Haemophilia a Prophylaxis in Europe
2020
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI